Package insert for CorgardrG, ER Squibb and Sons, Inc., December, 1979.
2.
DreyfussJShawJMMitlerTM.Nadolol: placental transfer and excretion in the milk of rats. Toxicol Appl Pharmacol1977; 39: 275–83.
3.
LeeRJEvansDBSherrinHBLaffanRJ.Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depression. Eur J Pharmacol1975; 33: 371–82.
4.
LeeGDe MariaANMillerRRComparative effects of nadolol and propranolol on cardiac and peripheral circulatory function in patients with coronary artery disease. Clin Res1978; 26: 100A.
5.
Le WinterMMCurtisGPEnglerRLShebetaiRVerbaJ.Effects of equiblocking doses of nadolol and propranolol on left ventricular performance. Clin Pharmacol Ther1979; 26: 162–6.
6.
LeeRJDickersonDDFulmorIEGoldbergME.Comparative effects of selected β-adrenergic blocking agents on myocardial contractility in conscious atherosclerotic rabbits. Pharmacologist1977; 19: 133A.
7.
ParkhamCSEvansDBLaffanRJGoldbergME.Comparative study of myocardial β-adrenergic blockade and inotropic action of nadolol (N) with other β-adrenergic blocking agents. Pharmacologist1977; 19: 133A.
8.
FrishmanW.Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1: pharmacodynamic and pharmacokinetic properties. Am Heart J1979; 97: 666.
9.
EvansDBPeahkaMTLeeRJLaffanRJ.Anti-arrhythmic action of nalolol, a β-adrenergic receptor blocking agent. Eur J Pharmacol1976; 35: 17–27.
10.
GibsonJKGelbandHBassettAR.Direct and beta-adrenergic blocking actions of nadolol (SQ 11725) on electrophysiologic properties of isolated canine myocardium. J Pharmacol Exp Ther1977; 202: 702–10.
11.
VukovichRASasaharaAZombranoPBelkoJGodinPBrannickL.Antiarrhythmic effects of a new beta-adrenergic blocking agent, nadolol. Clin Pharmacol Ther1976; 19: 118A.
12.
FrithzG.Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension. Curr Med Res Opin1978; 5: 383–7.
13.
DuchinKLVukovichRADennickLGGroelJTWillardDA.Effects of nadolol β-blockade on blood pressure in hypertension. Clin Pharmacol Ther1980; 27: 57–63.
14.
VolicerLLlangCSGavrasHEffect of nadolol in treatment of hypertension. J Clin Pharmacol1979; 19: 137–47.
15.
HollenbergNKAdamsDFMcKinstryDNWilliamsGHBornckiLJSullivanJM.β-adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation. Br J Clin Pharmacol1979; 7: 2195–245.
16.
FoleyJEGriffithDLBrannickJAllimonosMEWillardDAVukovichRA.Effects of β-adrenergic blockade with nadolol (N) and propranolol (P) on isoproterenol (I)-induced Iipolysis. Clin Res1978; 26: 590A.
17.
DreyfussJBrannickLJVukovichRAShawJMWillardDA.Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol1977; 17: 300–7.
18.
DreyfussJGriffithDLSingliviSMPharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single and multiple-dosage regimens to hypertensive patients. J Clin Pharmacol1979; 19: 712–20.
19.
VukovichRAFoleyJEBrownBEffect of β-blockers on exercise double product (systolic blood pressure × heart rate). Br J Clin Pharmacol1979; 7: 167S–72S.
20.
DuchinKLVukovichRADennickLGGroelJT.Steady-state pharmacokinetics of nadolol and therapeutic efficacy. Clin Pharmacol Ther1979; 25: 221A.
21.
HerreraJVukovichRAGriffithDL.Elimination of nadolol by patients with renal impairment. Br J Clin Pharmacol1979; 7: 227S–31S.
22.
FrishmanWSilvermanR.Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2, physiologic and metabolic effects. Am Heart J1979; 97: 800.
23.
FurbergBDahlqvistARaakAWregeU.Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris. Curr Med Res Opin1978; 5: 388–93.
24.
TurnerGGNelsonRRNordstromLADiefenthalHCGobelFL.Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris. Br Heart J1978; 40: 1361–70.
25.
El MehairyMMShakerARamadanMHamazaSTadrosSS.Long-term treatment of essential hypertension using nadolol and hydrochlorothiazide combined. Br J Clin Pharmacol1979; 7: 199S–203S.
26.
El MehairyMMShakerARamadanMHamazaS.Nadolol and propranolol in the treatment of hypertension: a double-blind comparison. J Int Med Res1980; 8: 193–8.
27.
VukovichRAZambranoSGSaraharaAABelkoJ.Refractory arrhythmia in the presence of congestive heart failure: successful beta-sympatholytic treatment (case report). Am Heart J1979; 98: 399–400.
28.
FrishmanWJacobHEisenbergERibnerH.Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8, self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J1979; 98: 798–811.
29.
FrishmanWSilvermanRStromJElkayamUSonnenblickE.Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4, adverse effects. Choosing a β-adreno-receptor blocker. Am Heart J1979; 98: 256–62.
30.
OkaYFrishmanWBeckerRMClinical pharmacology of the new beta-adrenergic blocking drugs. Part 10, beta-adrenoceptor blockade and coronary artery surgery. Am Heart J1980; 99: 255–69.
31.
SibleyPLKlimGRKuleszaPreclinical toxicologic evaluation of nadolol, a new β-adrenergic antagonist. Toxicol Appl Pharmacol1978; 44: 379–89.
